a year ago
VKTX
AnalystsRoger SongRoger Song's Stock Forecasts
AnalystsRoger Song
Analyst Ranking
Bottom 2%
#4875 out of 4929 analysts
Average Return
-14.43%
Win Rate
33%13 out of 40
Risk vs Reward
Poor
Good
Roger Song's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Atyr Pharma IncATYR | +203.43% | $1.75 | $5.31 | 2024-09-04 - 2025-07-03 | Strong Buy |
Nektar TherapeuticsNKTR | +167.24% | $9.27 | $24.76 | 2025-04-10 - 2025-07-03 | Strong Buy |
Sutro Biopharma IncSTRO | +92.81% | $11.27 | $21.72 | 2020-09-01 - 2021-08-31 | Strong Buy |
Akebia Therapeutics IncAKBA | +89.53% | $1.91 | $3.62 | 2025-03-31 - 2025-07-03 | Strong Buy |
Kinnate Biopharma IncKNTE | +76.67% | $1.50 | $2.65 | 2023-09-18 - 2024-04-02 | Strong Buy |
Roger Song Analyst Color
Get additional color on Roger Song's coverage of popular stocks
Roger Song's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Verve Therapeutics IncVERV | 1 | Hold | $11.00 | -2.48% | Downgrades | 19 days ago |
Curevac NvCVAC | 1 | Hold | $5.00 | -8.26% | Downgrades | 24 days ago |
Kiniksa Pharmaceuticals International PLCKNSA | 2 | Strong Buy | $45.00 | +61.41% | Maintains | 2 months ago |
Nektar TherapeuticsNKTR | 10 | Strong Buy | $30.00 | +21.16% | Upgrades | 3 months ago |
Akebia Therapeutics IncAKBA | 1 | Strong Buy | $6.00 | +65.75% | Initiates Coverage On | 3 months ago |
Sana Biotechnology IncSANA | 1 | Strong Buy | $7.00 | +119.44% | Initiates Coverage On | 4 months ago |
Krystal Biotech IncKRYS | 1 | Strong Buy | $245.00 | +71.23% | Initiates Coverage On | 4 months ago |
Wave Life Sciences LtdWVE | 1 | Strong Buy | $26.00 | +274.10% | Initiates Coverage On | 4 months ago |
Igm Biosciences IncIGMS | 2 | Hold | $2.00 | +47.06% | Downgrades | 6 months ago |
Bioage Labs IncBIOA | 2 | Hold | $7.00 | +63.55% | Downgrades | 7 months ago |
Replimune Group IncREPL | 1 | Strong Buy | $19.00 | +102.13% | Maintains | 7 months ago |
Kura Oncology IncKURA | 2 | Strong Buy | $28.00 | +377.82% | Maintains | 8 months ago |
Aclaris Therapeutics IncACRS | 1 | Strong Buy | $7.00 | +386.11% | Upgrades | 8 months ago |
Disc Medicine IncIRON | 1 | Strong Buy | $89.00 | +62.56% | Initiates Coverage On | 8 months ago |
Novavax IncNVAX | 2 | Strong Buy | $25.00 | +267.65% | Maintains | 9 months ago |
Nurix Therapeutics IncNRIX | 1 | Strong Buy | $41.00 | +222.07% | Initiates Coverage On | 9 months ago |
Zenas Biopharma IncZBIO | 1 | Strong Buy | $35.00 | +248.95% | Initiates Coverage On | 9 months ago |
Atyr Pharma IncATYR | 1 | Strong Buy | $9.00 | +69.49% | Initiates Coverage On | 10 months ago |
Vaxcyte IncPCVX | 1 | Strong Buy | $129.00 | +287.97% | Maintains | 10 months ago |
Cytomx Therapeutics IncCTMX | 2 | Strong Buy | $8.00 | N/A | Upgrades | a year ago |
Nuvalent IncNUVL | 1 | Strong Buy | $97.00 | N/A | Initiates Coverage On | a year ago |
Tourmaline Bio IncTRML | 2 | Strong Buy | $72.00 | N/A | Maintains | a year ago |
Viking Therapeutics IncVKTX | 1 | Strong Buy | $110.00 | N/A | Initiates Coverage On | a year ago |
Kinnate Biopharma IncKNTE | 2 | Strong Buy | $2.00 | N/A | Maintains | 2 years ago |
Altimmune IncALT | 1 | Strong Buy | $35.00 | N/A | Maintains | 3 years ago |
Prelude Therapeutics IncPRLD | 1 | Strong Buy | $9.00 | N/A | Initiates Coverage On | 3 years ago |
Whitehawk Therapeutics IncWHWK | 1 | Strong Buy | $675.00 | N/A | Initiates Coverage On | 3 years ago |
Corvus Pharmaceuticals IncCRVS | 1 | Strong Buy | $8.00 | N/A | Initiates Coverage On | 4 years ago |
Crescent Biopharma IncCBIO | 1 | Strong Buy | $4.00 | N/A | Upgrades | 4 years ago |
Atreca IncBCEL | 1 | Strong Buy | $30.00 | N/A | Initiates Coverage On | 4 years ago |
Molecular Templates IncMTEM | 1 | Strong Buy | $315.00 | N/A | Initiates Coverage On | 5 years ago |
Sutro Biopharma IncSTRO | 1 | Strong Buy | $21.00 | N/A | Initiates Coverage On | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.